Welcome to the e-CCO Library!

P777 Clostridioides difficile infection in children with inflammatory bowel disease: A Canadian population-based study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. El-Matary1, A. Chandrakumar2, H. Zohni2

Created: Thursday, 30 January 2020, 10:12 AM
P777: Comparison of costs of different biologic therapies after dose optimisation
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Borzan1,2, V. Orsic Fric1,2*, B. Borzan2

Created: Thursday, 21 February 2019, 9:14 AM
P777: Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1)*;Rubin, D.(2);Weber, C.(3);Adsul, S.(4);Freire, M.(4);Biedermann, L.(5);Koelzer, V.(6);Bressler, B.(7);Xiong, W.(8);Niess, J.(9);Matthias Matter, M.M.(9);Kopylov, U.(10);Barshack, I.(11);Mayer, C.(11);Magro, F.(12);Carneiro, F.(13);Maharshak, N.(14);Greenberg, A.(15);Hart, S.(16);Dehmeshki, J.(17);Kubassova, O.(16);
Created: Friday, 14 July 2023, 11:12 AM
P777: The cancer incidence in paediatric onset inflammatory bowel disease: a population-based study from Denmark
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Malham*1, C. Jakobsen1,2, A. Paerregaard1, L. B. Riis3, K-L. Kolho4, V. Wewer1

Created: Friday, 22 February 2019, 9:41 AM
P777: Ursodeoxycholic acid and its taurine/glycine conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Van den Bossche L.*1, Hindryckx P.1, Devisscher L.1, Devriese S.1, Van Welden S.1, Holvoet T.1, Vilchez-Vargas R.2, Vital M.3, Pieper D.H.3, Vanden Bussche J.4, Vanhaecke L.4, Van de Wiele T.2, De Vos M.1, Laukens D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P778 Longitudinal trajectory of fatigue in inflammatory bowel disease patients: a prospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Borren1, M. Long2, J. van der Woude3, R. Sandler2, A. Ananthakrishnan1

Created: Thursday, 30 January 2020, 10:12 AM
P778: Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: García, M.J.(1)*;Riestra, S.(2);Amiot, A.(3);Julsgaard, M.(4);García de la Filia, I.(5);Calafat, M.(6);Aguas, M.(7);de la Peña, L.(8);Roig-Ramos, C.(9);Caballol, B.(10);Casanova, M.J.(11);Farkas, K.(12);Boysen, T.(13);Bujanda, L.(14);Cuarán, C.(15);Dobru, D.(16);Fousekis, F.(17);Gargallo-Puyuelo, C.J.(18);Savarino, E.(19);Calvet, X.(20);Huguet, J.M.(21);Kupcinskas, L.(22);López-Cardona, J.(23);Raine, T.(24);van Oostrom, J.(25);P. Gisbert*, J.(11);Chaparro*, M.(11);
Created: Friday, 14 July 2023, 11:12 AM
P778: Microbial characterization of paediatric inflammatory bowel disease and stratification into disease severity groups
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Olbjørn C.*1,2, Cvancarova Småstuen M.3, Casén C.4, Nakstad B.1,2, Lindahl T.4, Rove J.B.1, Thiis-Evensen E.5, Vatn M.H.6, Perminow G.7

Created: Wednesday, 20 February 2019, 10:36 AM
P778: Real-world drug treatment costs for ulcerative colitis and Crohn’s disease patients treated with vedolizumab vs. anti-TNFα: Results from a German retrospective chart review study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Campbell-Hill1*, D. Stein2, M. Soni2, C. Coombs3, B. Ratsch4, J.M. Khalid1, K. Minda5

Created: Thursday, 21 February 2019, 9:14 AM
P778: Risk of cancer in paediatric onset inflammatory bowel disease: a nationwide cohort study 1977–2014
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. S. Kjærgaard1,2, C. B. Jensen1, J. Burisch1,3, K. Allin1, T. Jess*1

Created: Friday, 22 February 2019, 9:41 AM
P779 Intestinal cancer associated with Crohn’s disease: difference between those with short duration and those with long duration
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Shinozaki, R. Takahashi

Created: Thursday, 30 January 2020, 10:12 AM
P779: CD patients in deep remission harbor a high dysbiosis index similar to active CD at diagnosis, yet both are higher in comparison to healthy controls
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Haberman Y.*1,2, Klein T.1, Di Segni A.1, Neuman S.1, Levhar N.1, Bubis M.1, Picard O.1, BenShoshan M.1, Farage Barhom S.1, Glick Saar E.1, Cesarkas K.1, Lahad A.1, Shouval D.1, Weiss B.1, Eliakim R.1, Ben-Horin S.1, Kopylov U.1 Israeli IBD Research Nucleus (IIRN)

Created: Wednesday, 20 February 2019, 10:36 AM
P779: Clinical outcome with biological therapy in ulcerative colitis: Real-world clinical setting from a multi-centre observational study
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Ramos1*, A. Hernandez Camba1, R. De La Barreda1, M. Vela2, I. Alonso-Abreu1, R. Gloria Esther2, M. Carrillo-Palau1, C. Tardillo2, Y. Rodríguez2, A. Figueroa Marrero3, D. Ceballos3, N. Cruz4, L. Kolle Casso5, A. Jiménez6, E. Quintero Carrión1,7

Created: Thursday, 21 February 2019, 9:14 AM
P779: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Casellas Jorda, F.(1)*;Rodríguez, C.(2);Gisbert, J.P.(3);Bernardo, S.(4);Aparicio, J.(5);Tagarro, I.(5);Muñoz, F.(6);
Created: Friday, 14 July 2023, 11:12 AM
P779: Extra intestinal manifestations and other comorbidities in Crohn’s disease and Ulcerative colitis are equally likely to appear before IBD diagnosis: a Danish nationwide registry study from 2003 to 2015
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Vadstrup*1, S. Alulis1, A. Borsi2, T. R. Jørgensen3, A. Nielsen4, P. Munkholm5, N. Qvist6

Created: Friday, 22 February 2019, 9:41 AM
P780 Proteinuria is associated with the development of Crohn’s disease: a nationwide population-based study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.S. Kim, S. Park, H.J. Lee, H. Soh, J.M. Moon, S.W. Hong, E.A. Kang, J.P. Im

Created: Thursday, 30 January 2020, 10:12 AM
P780: 3-oxo-C12:2-HSL, a new N-acyl-homoserine lactone identified in gut ecosystem exerts an anti-inflammatory effect and does not modify paracellular permeability
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Le Balc'h E.*1, Landman C.1, Tauziet E.1, Brot L.1, Quevrain E.1, Rainteau D.1, Grill J.-P.1, Thenet S.2, Seksik P.1

Created: Wednesday, 20 February 2019, 10:36 AM
P780: Interchangeability by a biosimilar of infliximab: What do patients think?
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Baudrant1*, A. Roche1, B. Allenet1, L. Grange2, L. Bouillet3, N. Mathieu4, B. Bonaz4

Created: Thursday, 21 February 2019, 9:14 AM
P780: Medical treatment and surgery in patients with elderly-onset inflammatory bowel disease: 3-year follow-up of Epi-IBD 2010–2011 cohorts
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Hernandez*1, J. Martinez-Cadilla1, E. Langholz2, D. Christodoulou3, S. Turcan4, D. Valpiani5, P. L. Lakatos6, Z. Vegh6, A. Goldis7, E. Belousova8, K. Ladefoged9, G. Kiudelis10, D. McNamara11, O. Shonova12, Z. Krznarić13, F. Magro14, E. S. Bjornsson15, S. Almer16, M. Fumery17, D. Duricova18, A. Kievit19, I. Kaimakliotis20, P. Ellul21, O. Niewiadomski22, M. Giannotta23, S. Odes24, N. Pedersen25, J. F. Dahlerup26, J. F. Dahlerup26, R. Salupere27, R. D'Incà28, R. D'Incà28, J. Halfvarson29, P. Oksanen30, N. Arebi31, K. R. Nielsen32, V. Andersen33, S. Shaji34, P. Munkholm35, J. Burisch35, Epi-IBD-group1

Created: Friday, 22 February 2019, 9:41 AM
P780: Prognosis and optimal treatment for 5-aminosalicylic acid-intolerant patients with Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yaguchi, K.(1,2)*;Kinoshita, H.(1);Kunisaki, R.(1,2);Madarame, A.(1);Tatsuno, M.(1);Nishikawa, Y.(1);Hama, T.(1);Onishi, M.(1);Kobayashi, K.(1);Shibui, S.(1);Toritani, K.(1);Nishida, D.(1);Matsubayashi, M.(1);Nakamori, Y.(1);Nishio, M.(1);Umezawa, S.(1);Ogashiwa, T.(1);Sasaki, T.(1);Fujii, A.(1);Kimura, H.(1);Kato, J.(3);Maeda, S.(2);
Created: Friday, 14 July 2023, 11:12 AM